COMMUNIQUÉS West-GlobeNewswire

Cannabix Marijuana Breath Test Clears Key Regulatory Milestone: Handheld Breath Collection Unit (BCU) Passes FCC Electronic Emissions Testing
09/12/2025
VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce that the Cannabix Breath Collection [...]
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
09/12/2025
Financing from new and existing healthcare focused investors The proceeds are expected to extend the Company’s cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that [...]
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
09/12/2025
Weinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $ 5 billion in exits across healthcare, biotechnology, and [...]
A.D.A.M. Innovations Announces the Launch of ALUNAÉ
09/12/2025
The World’s First AI Genomic-Based Skincare Line Designed to Address Japanese and Asian Environmental Skin Aging TOKYO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese corporate name: Genesis [...]
Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth
09/12/2025
SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, [...]
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
09/12/2025
HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of [...]
FOXO Technologies Inc. Subsidiary, Myrtle Recovery Centers, Recognized by the Rural Health Association of Tennessee for Outstanding Community Impact
09/12/2025
WEST PALM BEACH, FL, Dec. 09, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., was recently [...]
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
09/12/2025
Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial [...]
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
09/12/2025
No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient life Barzolvolimab is the only drug in development to demonstrate clinical benefit in patients in [...]
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
09/12/2025
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 1 Olanzapine LAI is designed to help support real [...]
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
09/12/2025
PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision
09/12/2025
Company Finalizes GlycoCheck® License, Advances DocSun AI Acquisition and SDK Partnerships, and Engages Investment Bank for Planned 2026 Initiatives CHATTANOOGA, Tenn., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BioRegenx, Inc [...]
Tessera Therapeutics Announces Chief Financial Officer (CFO) Transition and Appointment of Kathy Bergsteinsson as CFO
09/12/2025
SOMERVILLE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced a planned leadership transition [...]
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
09/12/2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000 ® Index and the broad-market [...]
Codetta Bio™ Expands Global Commercial Leadership to Accelerate Worldwide Adoption of the Concerto™ System
09/12/2025
DURHAM, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Codetta Bio™, a leading innovator in multi-omic solutions that integrate ultrasensitive protein quantitation with simultaneous analysis of nucleic acids (RNA and DNA), [...]
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
09/12/2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet [...]
ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science
09/12/2025
Xelafaslatide was safe and well tolerated at all evaluated doses, with the potential to reduce GA lesion growth and improve vision ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical- [...]
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
09/12/2025
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 2025 1 , and core [...]
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
09/12/2025
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP [...]

Pages